COPD surprise: In majority, FEV1 declines no faster than healthy people’s (NEJM)
Posted Jan 28 2013 12:08pm
If you have COPD your FEV1 may, or, may not decline. If you smoke it will decline. If you do not smoke, your FEV1 may not decline any faster than that of a healthy nonsmoker.
Why are you smoking, again? “It doesn’t matter…” is not true.
Funny, the Doctor’s are surprised to learn that all of us are different. It is something that those of us with COPD, sharing our experience, for the benefit of others, on ”Social Media,” already know. WE are all different. Quit treating the disease, and start treating the person. You do not need further study to start making that part of the treatment protocol. Do you?
And, if you have COPD, and still smoke. Quit. Now. You will probably live longer, if you motivate yourself to quit smoking. Here is proof.
” Current smoking did markedly accelerate FEV1 decline, by an additional 21 mL/year.”
COPD is a progressive disease causing inexorable decline in lung function, right? We were all taught it, but maybe no one checked first. Vestbo et al’s ECLIPSE , a simple but large and elegant observational study that continues to furnish new insights into COPD, shows the truth is far more nuanced and complicated.
After following 2,163 patients with COPD of varying severity for 3 years, a complex tapestry of patients emerged. The mean rate of decline in FEV1 was 33 mL/year — not far off from the 20 to 30 mL/year loss observed in healthy nonsmokers in one major study . But people with COPD varied widely in their rates of FEV1 decline: the standard deviation between individuals was 59 mL — almost twice the mean (that’s big). Other interesting points included:
Only 38% had a decline of more than 40 mL/year over the 3 years.
Fewer than half exceeded a loss of 30 mL/year (the upper limit of physiologic decline).
Fully 8% had an increase in FEV1 of more than 20 mL/year.
The worse the COPD stage (FEV1), the slower the rate of decline, suggesting COPD may “burn out” over time (authors’ words). Conversely, those with milder COPD had faster FEV1 loss.
Cumulative smoking (pack-years) had no effect on rate of FEV1 decline.
Current smoking did markedly accelerate FEV1 decline, by an additional 21 mL/year.
Exacerbations were only weakly associated with accelerated decline of FEV1, by 2 mL/year per exacerbation experienced during the study.
Emphysema on CT was associated with an increased FEV1 decline of 13 mL/year. Interestingly, a bronchodilator response on spirometry predicted an accelerated FEV1 decline of 17 mL/year.
Treatment may have slowed the rate of FEV1 decline in some patients (making this even more complicated): patients were on standard care throughout, and medications such as inhaled corticosteroids/long-acting beta agonists slow decline in lung function.